Intarcia Therapeutics is primed to file its potentially revolutionary diabetes drug delivery device after revealing positive cardiovascular safety results.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
